Armata Pharmaceuticals, Inc. 10-Qquarter ended 2026-03-31

Executive Summary

Armata Pharmaceuticals is advancing bacteriophage treatments for difficult-to-treat infections, with its lead program, AP-SA02, moving toward a Phase 3 bacteremia trial after favorable Phase 2 results and regulatory feedback. Q1 2026 grant revenue rose and operating cash use fell, but higher development spending and interest expense continued to pressure the business; a noncash convertible-loan revaluation drove most of the $115M reported loss. Cash at 03/31/2026 was insufficient to fund the following 12 months, prompting a going-concern warning despite a $25.0M secured loan obtained after quarter-end. For investors, the clinical opportunity is substantial, but its value depends on financing a pivotal trial without excessive dilution or further balance-sheet strain.

Key Financial Highlights

• Operating expenses: $9.57M vs $8.68M, including R&D of $6.11M vs $5.43M. Laboratory supplies, manufacturing engineering runs and personnel costs supported development and regulatory preparation.
• Earnings quality: A $101M noncash fair-value loss on the convertible loan replaced a $5.20M gain a year earlier. The resulting GAAP-loss swing substantially exceeded the change in operating cash use.
• Financing costs: Interest expense increased to $5.56M from $3.60M, reflecting higher borrowing balances and amortization of debt discounts and issuance costs. Stock-based compensation was $1.08M.

Business Developments

AP-SA02 is the principal near-term value driver. In its completed Phase 2a study of complicated S. aureus bacteremia, investigator-assessed day-12 response was 88% with AP-SA02 plus antibiotics versus 58% with antibiotics alone. Following its end-of-Phase-2 review, FDA feedback supported advancement to a Phase 3 superiority study and addressed trial design, manufacturing and a potential licensing application. Armata expects to start the ≈450-patient study in H2 2026, subject to funding. The FDA designated intravenous AP-SA02 a Qualified Infectious Disease Product, potentially providing additional exclusivity if approved; a Fast Track request has been submitted, but designation has not been reported.

The $26.2M cost-reimbursable MTEC award supports AP-SA02 work and runs through 09/30/2026. Armata’s manufacturing process improvements have increased phage titers and purity and improved production consistency, capabilities relevant to a larger trial and eventual supply.

AP-PA02 offers a second clinical opportunity, but its Phase 2 study missed significant treatment-placebo differences in prespecified individual-cohort analyses; favorable pooled results came from a post-hoc analysis. A definitive Phase 3 trial requires financing or a partner. Preclinical AP-PA03 development is likewise funding-dependent, making near-term resource allocation heavily dependent on the AP-SA02 financing plan.

Risk Assessment

• Going concern and liquidity: Management says existing cash cannot fund operations for 12 months after issuance of the statements and identifies substantial doubt about Armata’s ability to continue as a going concern; failure to raise capital could delay trials or force program cuts.
• Secured financing burden: A convertible loan with $30.0M principal and four term loans with $85.0M aggregate original principal are secured by substantially all relevant assets; three term loans and the convertible loan mature on 06/01/2027, creating financing and refinancing pressure.
• Dilution and financing terms: Shares reserved for future issuance totaled 46.1M versus 36.6M shares outstanding; the convertible loan alone represented 24.9M issuable shares, while further equity funding or partnerships could dilute holders or surrender product rights.
• Clinical and execution risk: The proposed AP-SA02 pivotal trial must confirm the smaller Phase 2 result at greater scale, while AP-PA02’s encouraging pooled findings do not reverse its inconclusive prespecified cohort analyses.
• Valuation volatility: The Level 3 convertible loan’s fair value rose to $255M from $154M; its valuation assumes 100% equity conversion, so stock-price and model changes can sharply move GAAP earnings without corresponding operating cash flows.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

The $25.0M secured Innoviva Sub loan entered on 05/12/2026 provides funding after quarter-end, but carries 14.0% annual interest and does not eliminate the going-concern warning or the need to fund Phase 3. The investment case turns on whether Armata can convert AP-SA02’s clinical and regulatory progress into a financed pivotal program while containing dilution and debt costs.

• AP-SA02 launch: Monitor whether the ≈450-patient Phase 3 trial begins in H2 2026 and whether its financing is secured.
• Liquidity and funding terms: Track unrestricted cash, operating cash use and new capital against the company’s stated funding shortfall; assess dilution or rights concessions, not just proceeds raised.
• Debt and valuation: Monitor interest expense, progress toward 06/01/2027 maturities and convertible-loan fair value separately from operating performance.